DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Comparing 0.5 mg Dutasteride vs Placebo Daily in Men Receiving Androgen Ablation Therapy for Prostate Cancer

Information source: Canadian Urology Research Consortium
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Prostate Cancer

Intervention: Dutasteride (Drug)

Phase: Phase 2/Phase 3

Status: Active, not recruiting

Sponsored by: Canadian Urology Research Consortium

Official(s) and/or principal investigator(s):
Laurence Klotz, MD, Principal Investigator, Affiliation: CURC
Larry S Goldeng, Principal Investigator, Affiliation: CUOG


Patient on an intermittent androgen deprivation protocol for biochemical recurrence after radical local therapy for prostate cancer,the addition of continuous dutasteride treatment, significantly prolongs the duration of the off treatment interval and time to androgen independence.

Clinical Details

Official title: Multi Center Double Blind Study Comparing 0.5 mg Dutasteride vs Placebo Daily in Men Receiving Intermittent Androgen Ablation Therapy for Prostate Cancer

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention

Primary outcome: To assess whether repeat oral once daily dosing of dutasteride 0.5mg increases the length of the off treatment interval in men receiving intermittent androgen ablation therapy for localized prostate cancer

Detailed description: The study is to assess the effect of therapy with repeat oral daily dosing of dutasteride 05 mg on the length of the off treatment interval in men receiving intermittent androgen therapy for localized prostate cancer.


Minimum age: 45 Years. Maximum age: 80 Years. Gender(s): Male.


Inclusion Criteria:

- Able to give informed consent

- Age_>45and<_80

- Histological confirmed adenocarcinoma of prostate

- Has received external beam radiation,brachytherapy or radical prostatectomy for the

treatment of prostate ca

- Candidate for intermittent androgen ablation

- Minimum of 3 PSA values above nadir taken at least 1 month apart

- Serum testosterone >_250ng/dl,ECOG 0 or 1

- Negative bone scan within 12 months of visit 1

- Able to swallow and retain oral medication

Exclusion Criteria:

- Previous treatment with chemotherapy

- Hormonal therapy with in last year

- Glucocorticoid with in last 3 months

- LHRH analogues with in previous year

- Ketoconazole

- Non Steroidal anti-androgens with in previous year

- Concurrent or previous use of Finasteride Dutasteride 5a reductase inhibitor anabolic


- Over the counter or herbal prep such as saw palmetto selenium or vitamin E within

last year

- May not be receiving any other investigational drug with in last 30 days

- Evidence of distant metastases

- Has received adjuvant or neoadjuvant ablation in past 12 months

- Unstable serious co-existing medical condition

- Abnormal liver and kidney functions

- Previous malignancy not including curative treated basal cell carcinoma of skin with

in 5 years and bladder cancer with in past 2 years

- Known hypersensitivity to any 5a-reductase inhibitor or to any drug chemically

related to dutasteride

- Known hypersensitivity to bicalutamide.

Locations and Contacts

Sunnybrook Health Sciences Centre, Toronto, Ontario M4N 3M5, Canada
Additional Information

Starting date: March 2007
Last updated: July 31, 2012

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017